OmniRx Research // Data Study

PBM Reality 2026: Cross-Referencing 55 Patient Assistance Programs and 50 Insurer Formularies

Cite this dataset: DOI 10.5281/zenodo.24322567 (CC-BY 4.0) · all versions

How do patient assistance programs and insurer formulary coverage overlap in 2026? Cross-referencing 55 PAPs and 50 insurer formularies against the FTC and GAO PBM policy backdrop.

Last updated:
Bottom line: Across two first-party OmniRx datasets (55 patient assistance programs, 50 formulary records), 65.5% of patient assistance programs are run by manufacturers. The FTC's July 2024 Interim Staff Report on PBMs and its January 2025 follow-up establish the regulatory framing; this audit attaches first-party patient-facing data to that frame.
Correction, 13 November 2026 This study originally included a 53-record drug-interaction component: severity grades, a most-flagged-drugs ranking and an overlap with drug coverage. Those records were compiled by hand and were not checked against current FDA label text. An audit of the OmniRx interaction pages found statements that did not match the labels, so the component and every figure derived from it have been withdrawn from this page, from data.json and from the press kit. The patient-assistance and formulary findings below are unchanged. Archived earlier versions of this study may still contain the withdrawn component.
Correction, 15 November 2026 A recount of this study against the live program database could not reproduce its income-limit distribution (Finding 3), its drug-overlap ranking (Finding 8) or its formulary tier-count comparison (Finding 5), so all three have been withdrawn from this page and from data.json. The program count (55) and the sponsor-type split (Finding 4) do reproduce and are unchanged. The earlier published versions (v1.0 and v1.1) still contain the withdrawn figures and are superseded by version 2.0.2 (DOI 10.5281/zenodo.24322567).
Correction, 17 November 2026 Finding 7 said five of the 25 drug-coverage entries (20%) were GLP-1 or weight-loss drugs. An independent recount finds four (Ozempic, Wegovy, Mounjaro and Zepbound), which is 16%. The earlier wording counted a fifth entry that does not fit the description. The corrected figure is in version 2.0.2 (DOI 10.5281/zenodo.24322567).
Medical disclaimer This research is for informational purposes. Drug pricing data reflects publicly disclosed formulary information; individual experience varies by plan, region, and effective date. Consult your pharmacist or physician for personalized guidance. Do not change or stop a prescribed medication based on this dataset.
Editorial review status This study is pending review by a credentialed clinician. Author Vincent is a research lead, not a licensed healthcare professional. Quantitative findings (counts and distributions) are reproducible from the published data.json. Clinical interpretations are conservative and link to primary regulatory or peer-reviewed sources where possible.

Methodology

This audit cross-references two first-party OmniRx datasets compiled and maintained at omnirx.org:

For PBM industry context we draw on the Federal Trade Commission's July 2024 Interim Staff Report on Pharmacy Benefit Managers and the January 2025 second interim report. The FTC reports document that the three largest PBMs (CVS Caremark, Express Scripts, OptumRx) processed roughly 79% of U.S. prescription claims in 2023 and that vertical integration with insurers and specialty pharmacies has compressed independent pharmacy reimbursements while preserving rebate retention by the PBM. Our audit attaches consumer-facing data (PAPs, formulary explainers) to the regulatory frame the FTC has established.

Exclusions and limitations. Insurer formulary records describe tier structure rather than enumerating per-drug tier placement at full plan-by-plan scale; readers seeking specific tier placement for a specific drug on a specific plan should consult their plan's formulary document directly. PAP enrollment and approval rates are not publicly disclosed by manufacturers and are not in this dataset. PBM rebate retention data is summarized at the industry level, not the per-drug level. GAO's 2019 report on PBMs (GAO-19-498) and Drug Channels Institute coverage by Adam Fein supply the broader industry context.

Public dataset and pre-computed aggregates are available at data.json under a CC-BY 4.0 license. Source records live in OmniRx's assistance and formulary sections.

Finding 3: income limits (withdrawn 15 November 2026)

Headline: withdrawn. The income-limit distribution could not be reproduced from the program database.

This section reported how many of the 55 programs cap eligibility at each income level. A recount against the live program database (program records carry last-verified dates from 4 August to 4 October 2026) could not reproduce those counts: the database holds a structured income ceiling for only 21 of the 55 programs, so the distribution has been withdrawn. For one program's current limit, read that program's own page.

Finding 4: 65.5% of patient assistance programs are manufacturer-run, not independent

Headline: 36 manufacturer, 13 nonprofit, 4 federal, 2 discount-card

Manufacturer-run programs make up 65.5% of the OmniRx PAP catalog (36 of 55). Nonprofits account for 23.6% (13 of 55), federal programs 7.3% (4 of 55), and commercial discount cards 3.6% (2 of 55). The dominance of manufacturer programs is structurally important: a manufacturer PAP is a marketing-spend line item, not a charity, and is typically restricted to the manufacturer's own brand portfolio (Pfizer RxPathways covers Pfizer drugs; Lilly Cares covers Lilly drugs). Nonprofit copay funds like TotalAssist (the merged PAN Foundation and Patient Advocate Foundation) and HealthWell cover broader portfolios but exhaust funding cycles for many disease states. The federal layer (Medicare Extra Help, Medicaid, VA) catches the lowest-income patients but leaves many other patients to a patchwork of manufacturer programs that the patient or pharmacist must individually navigate. The structural critique embedded in the FTC PBM report applies here too: opacity benefits the intermediary, not the patient.

Patient assistance program type distribution Bar chart of PAP types: 36 manufacturer, 13 nonprofit, 4 federal, 2 discount. PAP sponsor type (n=55) 36 (65.5%)Manufacturer 13 (23.6%)Nonprofit 4 (7.3%)Federal 2 (3.6%)Discount card Number of programs
Source: OmniRx 2026 PAP database (n=55). Manufacturer programs are sponsor-specific by definition; nonprofit programs cycle funding by disease state.

Finding 5: formulary tier counts (withdrawn 15 November 2026)

Headline: withdrawn. The tier-count comparison did not match the insurer formulary pages.

This section reported how many tiers each insurer uses. It said UnitedHealthcare and Anthem use six, but the OmniRx formulary pages for those insurers describe 3 to 5 tiers depending on the plan, so the comparison and chart have been withdrawn. Tier counts differ by insurer and by plan; check your own plan's formulary document.

Finding 7: GLP-1 and weight-loss drugs occupy 16% of OmniRx's drug-coverage records

Headline: 4 of 25 drug-coverage entries are GLP-1 or weight-loss (Ozempic, Wegovy, Mounjaro, Zepbound)

Four of the 25 OmniRx drug-coverage entries (16%) cover GLP-1 receptor agonists or weight-loss-indicated drugs: Ozempic, Wegovy, Mounjaro and Zepbound. The concentration reflects the 2024-2026 demand surge that has reshaped formulary politics. KFF analysis documents that GLP-1s alone now account for a meaningful share of total Medicare Part D drug spending growth, and CMS has signaled that step-therapy and prior-authorization protocols for GLP-1s will be reviewed in 2026 plan-year rule-making. For patients, the practical effect is that the same active ingredient (semaglutide) is covered for one indication and not another (Ozempic for diabetes is covered, off-label for weight loss is not), and the brand-vs-brand routing through a PBM determines whether Wegovy, Zepbound, or compounded alternatives are accessible.

Finding 8: drug overlap (withdrawn 15 November 2026)

Headline: withdrawn. The drug-overlap counts did not match the current program database.

This section reported which drugs appear on the most patient assistance programs. A recount against the current database found 226 drug entries, not the 215 reported, and a different top list, so the ranking and chart have been withdrawn.

Finding 10: The same drug at the same wholesale cost can route through wildly different patient-out-of-pocket paths

Headline: Tier system + prior-auth + step-therapy + PAP availability = patient cost variance

This is the BLUF re-stated as a pricing thesis. A drug's wholesale acquisition cost is a small fraction of what determines a patient's out-of-pocket cost. The chain runs: PBM negotiates a list price and a rebate (rebate retained partly by PBM, partly passed to plan sponsor), insurer assigns a tier on its formulary (tier systems vary by insurer and plan), prior authorization or step therapy may be required, the patient's deductible and coinsurance phase determines the cost-share at point of sale, and a PAP may or may not exist to absorb residual cost. Mark Cuban Cost Plus Drugs is the operational counter-example: a transparent cost-plus-15%-plus-pharmacy-fee model that bypasses the PBM-rebate chain entirely for a curated drug list. The Cost Plus model is also documented in coverage by KFF Health News and STAT as the most credible existing test of the hypothesis that PBM rebate retention, not wholesale cost, is the dominant driver of patient-paid prices for the maintenance medications most patients take.

What this means for patients

Decision framework: how to read your formulary

Step 1: Know your tier system. Ask your insurer how many tiers your formulary uses. A tier number does not mean the same thing on every plan. The OmniRx formulary section documents tier systems for the 15 largest insurers and federal programs.

Step 2: Check PAP eligibility before paying full price. Many programs set an income limit, and the limits differ by program, so check the program page for the medicine you take. Manufacturer programs are easiest to find via the manufacturer's own website; nonprofit programs like the PAN Foundation cycle funding by disease state. The OmniRx assistance section indexes 55 programs.

Step 3: For maintenance generics, compare cash-pay alternatives. Mark Cuban Cost Plus Drugs, GoodRx, and Amazon Pharmacy can be cheaper than your insurance copay for generic maintenance medications. The PBM-rebate chain is structurally hostile to transparent cash pricing for generics.

Limitations to surface to your clinician

  1. This dataset captures publicly disclosed insurer formulary structure, not your specific plan's per-drug tier placement on a given effective date. Your insurer's portal is authoritative.
  2. PAP eligibility rules change. Always verify on the program's official website before relying on a stated income floor.

OmniRx is a consumer pharmacy intelligence site. We do not earn commission on PAP applications, formulary lookups, or Cost Plus orders, and we are not affiliated with any insurer or PBM. Editorial review of clinical content by a credentialed clinician is pending.

Press kit and downloads

Full press kit at /press/, machine-readable aggregates at data.json. Media inquiries via the contact on the press page. We are particularly interested in inquiries from KFF Health News, STAT, ProPublica, and other PBM-focused investigative desks.